We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+16.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$838M
AUM Growth
+$27.2M
Cap. Flow
-$59.8M
Cap. Flow %
-7.14%
Top 10 Hldgs %
41.9%
Holding
75
New
19
Increased
15
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$44.5M
2
BHC icon
Bausch Health
BHC
+$40.6M
3
CSLT
CASTLIGHT HEALTH, INC.
CSLT
+$34.3M
4
RAD
Rite Aid Corporation
RAD
+$23.2M
5
HCA icon
HCA Healthcare
HCA
+$22.6M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$48.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$34.3M
4
CELG
Celgene Corp
CELG
+$30.9M
5
AZN icon
AstraZeneca
AZN
+$30.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.72%
2 Miscellaneous 7.42%
3 Technology 2.82%
4 Communication Services 1.03%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
1
DELISTED
Allergan plc
AGN
$50.7M 6.06%
246,398
+74,158
+43% +$14.7M
HCA icon
2
HCA Healthcare
HCA
$90.5B
$45.8M 5.47%
872,589
+453,489
+108% +$22.6M
A icon
3
Agilent Technologies
A
$43.4B
$43.2M 5.16%
+1,080,646
New +$44.5M
BHC icon
4
Bausch Health
BHC
$2.36B
$39.2M 4.68%
+297,136
New +$40.6M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$35.5M 4.24%
513,198
-59,072
-10% -$4.34M
THC icon
6
Tenet Healthcare
THC
$21.5B
$33.8M 4.04%
789,562
+328,160
+71% +$14.5M
GMED icon
7
Globus Medical
GMED
$11.1B
$28.3M 3.37%
1,062,952
-23,685
-2% -$563K
HTWR
8
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$27.4M 3.27%
291,974
+69,951
+32% +$6.81M
RAD
9
DELISTED
Rite Aid Corporation
RAD
$23.8M 2.85%
+190,090
New +$23.2M
TVTY
10
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$23.2M 2.77%
1,354,832
+508,419
+60% +$7.83M
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
$22.9M 2.74%
4,882,930
+422,242
+9% +$2.12M
BMY icon
12
Bristol-Myers Squibb
BMY
$136B
$21.7M 2.6%
418,500
+17,630
+4% +$938K
PODD icon
13
Insulet
PODD
$10.1B
$21.7M 2.59%
457,048
+94,012
+26% +$4.16M
PRTA icon
14
Prothena Corp
PRTA
$479M
$21.4M 2.56%
559,611
+550,511
+6,050% +$17.7M
CSLT
15
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$20.8M 2.49%
+1,184,347
New +$34.3M
CMRX
16
DELISTED
Chimerix, Inc.
CMRX
$20.4M 2.44%
895,006
+148,601
+20% +$3M
NUVA
17
DELISTED
NuVasive, Inc.
NUVA
$20M 2.39%
521,301
-29,613
-5% -$1.09M
JAZZ icon
18
Jazz Pharmaceuticals
JAZZ
$15.9B
$19.8M 2.37%
142,886
-39,675
-22% -$5.97M
GWPH
19
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$19.2M 2.29%
323,583
-36,394
-10% -$2.16M
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.2M 2.17%
+1,001,060
New +$18.1M
PBYI icon
21
Puma Biotechnology
PBYI
$468M
$17.9M 2.14%
172,092
-58,581
-25% -$6.89M
KYTH
22
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$17.6M 2.1%
443,326
-114,435
-21% -$5.12M
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
$17.6M 2.1%
8,496,538
-151,549
-2% -$379K
ICPT
24
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$16.9M 2.01%
51,113
-214,836
-81% -$72.5M
CLDX icon
25
Celldex Therapeutics
CLDX
$3.07B
$15.3M 1.82%
57,596
+31,066
+117% +$11.9M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2014 Portfolio in Review

As of Q1 2014, Redmile Group held 75 positions worth $838M, up 3.4% from $810M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $59.8M in Q1 2014, closing 20 positions and reducing 20 holdings. Its most notable exit was Gilead Sciences, an estimated $48.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Agilent Technologies worth $43.2M.

  • Redmile Group's largest Q1 2014 buy was Agilent Technologies: 1,080,646 shares worth $43.2M.
  • Redmile Group added most to HCA Healthcare in Q1 2014, an estimated $22.6M increase.
  • Redmile Group's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $72.5M.
  • Redmile Group fully exited Gilead Sciences in Q1 2014, selling an estimated $48.6M.
  • Redmile Group's ten largest holdings make up 42% of its $838M portfolio in Q1 2014.
  • Redmile Group opened 19 new positions and closed 20 in Q1 2014.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $838M.

Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.